Ascidian Therapeutics
About Ascidian Therapeutics
Ascidian Therapeutics develops a proprietary RNA exon editing platform that enables precise post-transcriptional modifications to replace multiple contiguous exons, addressing genetic mutations that vary among patients. This technology allows for the production of full-length, functional proteins at appropriate levels and in the correct cells, providing a safer alternative to traditional gene editing methods.
```xml <problem> Many genetic diseases are caused by mutations that vary among patients, making them difficult to address with traditional gene therapies that target single base changes. Existing gene editing technologies may also carry risks associated with direct DNA modification or gene replacement. </problem> <solution> Ascidian Therapeutics is developing an RNA exon editing platform that enables precise post-transcriptional modification of RNA. This technology allows for the replacement of multiple contiguous exons, addressing genetic mutations that vary among patients. By rewriting RNA, Ascidian's approach aims to produce full-length, functional proteins at appropriate levels and in the correct cells, while maintaining endogenous gene expression patterns. This provides a potentially safer and more versatile alternative to traditional gene editing methods, without the risks of direct DNA editing or gene replacement. The platform is designed to expand the therapeutic possibilities of RNA medicine and treat diseases not addressed by current gene editing technologies. </solution> <features> - RNA exon editing platform for precise post-transcriptional modification - Ability to replace multiple contiguous exons, addressing diverse mutations - Production of full-length, functional proteins at appropriate levels - Maintains endogenous gene expression patterns and levels - Avoids the risks associated with direct DNA editing or gene replacement </features> <target_audience> The primary target audience includes researchers and pharmaceutical companies focused on developing treatments for genetic diseases with variable mutations. </target_audience> ```
What does Ascidian Therapeutics do?
Ascidian Therapeutics develops a proprietary RNA exon editing platform that enables precise post-transcriptional modifications to replace multiple contiguous exons, addressing genetic mutations that vary among patients. This technology allows for the production of full-length, functional proteins at appropriate levels and in the correct cells, providing a safer alternative to traditional gene editing methods.
Where is Ascidian Therapeutics located?
Ascidian Therapeutics is based in Boston, United States.
When was Ascidian Therapeutics founded?
Ascidian Therapeutics was founded in 2020.
How much funding has Ascidian Therapeutics raised?
Ascidian Therapeutics has raised 98130000.
- Location
- Boston, United States
- Founded
- 2020
- Funding
- 98130000
- Employees
- 51 employees
- Major Investors
- Apple Tree Partners